Impaired Fetal Growth, Cardiovascular Disease, and the Need to Move on

Wulf Palinski, MD; Claudio Napoli, MD, PhD, MBEth

The final step in the acceptance of a new medical hypothesis is often the approval of significant funding to investigate it. In the case of developmental programming (ie, the notion that the in utero environment determines susceptibility to many diseases later in life), this has recently come in the form of support by the US Congress for the National Children’s Study, a $3 billion project to follow the impact of environmental factors before, during, and after pregnancy on disease manifestation in some 100 000 children up to the age of 25 years.1 This initiative will, no doubt, yield a wealth of information to help understand the developmental programming hypothesis.

Much of the concept underlying the National Children’s Study stems from the pioneering work of Barker and colleagues,2 whose epidemiological observation of increased cardiovascular risk in children with low birth weight has spurred a large number of retrospective studies during the past 30 years. Despite some conflicting results, most of these studies support the notion that reduced birth weight is indeed associated with increased hypertension, diabetes mellitus, and cardiovascular disease. However, the strong correlation between birth weight and duration of gestation, plus the fact that a short gestation also may be associated with cardiovascular risk,3 poses the question to what extent low birth weight is truly responsible. In this issue of Circulation, an article by Kaisjer and coworkers4 at the Karolinska Institute in Stockholm provides a convincing answer. By scanning 250 000 records of birth at 4 major delivery units in Sweden between 1925 and 1949, they identified a cohort of 6437 subjects, which included 2937 children born preterm (<37 weeks of gestation) and 2181 with a birth weight <2100 g for girls or <2300 g for boys. During the follow-up period (1987 to 2002), 617 of these subjects were treated for or died of ischemic heart disease. Statistical analysis of these prospectively collected data indicated a strong negative correlation between birth weight adjusted for gestational duration and ischemic heart disease (P=0.002). Similarly, fetal growth (expressed as SD from the mean weight for gestational age indicated by fetal growth curves) was strongly associated with cardiovascular risk. In contrast, gestational duration adjusted for birth weight showed a positive association with risk (ie, children born before the 37th week had lower risk than term or postterm children, provided that they were not growth retarded). These results are consistent with those of previous, more limited studies and clearly indicate that the increased risk of coronary heart disease is associated with fetal growth restriction rather than premature birth, at least in subjects born before the advent of modern care for very premature births.

The Barker postulate—that impaired in utero growth is associated with increased cardiovascular risk later in life—can therefore be considered proven. But what has it taught us about the underlying pathogenic mechanisms, and what are their translational benefits? Ah, there’s the rub, for we ignore not only the pathogenic mechanisms of fetal programming but also its evolutionary significance, if any. It has been proposed that developmental programming constitutes an attempt by the fetus to prospectively adapt to detrimental conditions in utero such as undernutrition. Such “predictive adaptive programming” would be protective if the same conditions are encountered after birth but constitute a misadaption to the conditions of excessive caloric and fat consumption prevalent in most Western countries.5 It would also be difficult to correct after birth. Although many early indicators of cardiovascular risk encountered in childhood correlate with adult risk such as endothelial dysfunction and early atherosclerotic lesions6 and therefore constitute promising targets for intervention, compensating for low birth weight does not appear to be beneficial. In fact, accelerated growth during childhood seems to increase, not decrease, long-term risk,7 in particular in prematurely born children, in whom rapid early weight gain enhances insulin resistance and hypertension later in life.8 Thus, it appears that until the mechanisms of programming are better understood, little can be done after birth to reduce the effect of pathogenic in utero programming, except for a more rigorous avoidance of conventional cardiovascular risk factors. At least the need for earlier and more aggressive treatment of high-risk children is now beginning to be recognized in the latest guidelines.9

The focus on outcome parameters such as low birth weight or impaired fetal growth also has not been helpful in identifying specific maternal risk factors responsible for developmental programming. Low birth weight may result from a broad range of pathogenetically diverse maternal conditions, including mechanical obstructions of the uterine artery, severe maternal undernutrition or dysnutrition, corticosteroid treatment, and a number of metabolic diseases, most notably diabetes.10 It appears unlikely that these conditions would cause uniform pathogenic programming. Indeed, maternal diabetes may result not...
only in reduced birth weight but more frequently in macrosomia. Even if the maternal conditions were to influence birth weight in a consistent manner, sibling competition leads to wide disparities in birth weight, complicating the search for the factors responsible for developmental programming and enhanced disease susceptibility in offspring. Finally, it is now well recognized that maternal overnutrition, not undernutrition, will be the main health threat in the coming decades. The call to shift the emphasis away from birth weight and to focus on specific maternal risk factors and outcome parameters contributing to cardiovascular disease is therefore growing louder. We also should keep in mind that correlative epidemiological studies cannot establish causal relationships. Now that the influence of developmental programming has been established beyond doubt and the translational need is becoming more urgent, we need to go beyond epidemiology and put greater emphasis on experimental models suitable to investigate the mechanisms and causal relationships.

In contrast to animal models of low birth weight, which have yielded inconsistent results, much progress has been made recently in modeling some maternal conditions enhancing atherogenesis in human progeny such as maternal hypercholesterolemia. It has been established experimentally that maternal hypercholesterolemia and the ensuing increased oxidative stress not only accelerate atherosclerosis, as they do in humans, but also that they affect early predictors of cardiovascular disease in offspring such as arterial gene expression, endothelial function, and vascular reactivity. More important, multiple interventions in mothers have been shown to reduce or prevent this form of developmental programming. Programming by pregestational or gestational diabetes is more difficult to mimic, given the complexity of metabolic changes involved, and work on the role of maternal obesity and insulin resistance is only in its infancy. Increased inflammatory stress associated with these conditions, as well as with maternal hypercholesterolemia and smoking, is likely to be of central importance, as are immune mechanisms. Even mild inflammation may modulate immune responses in both the mother and fetus. In fact, evidence in animal models and humans indicates that maternal adaptive immunity programs B- or T-cell–dependent IgM responses in offspring. Similar programming of offspring IgA by maternal exposure to allergens also has been reported, but in contrast to allergic responses, an enhancement of postnatal immune defenses against cardiovascular, diabetic, or infectious antigens would be desirable, and maternal immunizations have already been shown to protect against postnatal atherogenesis, even in the absence of gestational hypercholesterolemia or hyperglycemia.

<table>
<thead>
<tr>
<th>Mother Pathology</th>
<th>Pregnancy Specific Factors Potentially Affecting Developmental Programming</th>
<th>Lactation Early Outcome Parameters:</th>
<th>Child Late Outcome Parameters:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under- or dysnutrition</td>
<td>Hypoxia</td>
<td>Birthweight</td>
<td>Clinically manifest</td>
</tr>
<tr>
<td>Corticosteroid treatment</td>
<td>Hypertension</td>
<td>Early changes in glucose metabolism</td>
<td>- CHD</td>
</tr>
<tr>
<td>Mechanical obstruction of uterine artery</td>
<td>Hyperglycemia</td>
<td>Oxidative stress markers</td>
<td>- Hypertension</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td>Hypercholesterolemia</td>
<td>Intimal thickening</td>
<td>- Diabetes</td>
</tr>
<tr>
<td>Obesity</td>
<td>Oxidative stress</td>
<td>Antigen-specific B or T cell populations</td>
<td>- Insulin resistance</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>B and T cell cytokines</td>
<td>IgM</td>
<td>- Diabetes</td>
</tr>
<tr>
<td>Diabetes</td>
<td>antibodies</td>
<td>Vitamin-specific IgM</td>
<td>- Infections</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>Pathogenic or Beneficial Programming Mechanisms</td>
<td>Conditions assessed by NCS:</td>
<td>- Allergy</td>
</tr>
<tr>
<td>Bacterial &amp; viral infections</td>
<td></td>
<td>- Obesity</td>
<td>and others</td>
</tr>
<tr>
<td>Allergies</td>
<td></td>
<td>- Hypertension</td>
<td></td>
</tr>
<tr>
<td>... and others</td>
<td></td>
<td>- Diabetes</td>
<td></td>
</tr>
</tbody>
</table>

**Figure.** Developmental programming of cardiovascular disease. Note that many of the maternal conditions and pathogenic factors are still hypothetical.
In addressing causal relationships, mechanisms, and preventive measures in experimental models, it is important to remember that maternal risk factors are not necessarily the same as those affecting the fetus. In addition to factors crossing the placental barrier by passive diffusion or active transport mechanisms (eg, maternal cholesterol), the placenta is both the target and a source of pathogenic factors reaching the fetus (the Figure). It can, for example, protect against or contribute to fetal oxidative stress induced by maternal hypercholesterolemia and/or vascular inflammation. The mechanisms shielding the placenta from recognition by the maternal immune system also may play a role in mediating inflammatory stress from mother to fetus. Another issue to be considered is the extent to which in utero programming is continued in the immediate postnatal period or during childhood. In humans, drastic changes in diet or exposure to environmental risk factors at birth are unlikely. We will therefore have to treat in utero programming, effects of lactation, and early postnatal programming as a single pathogenic entity.

The National Children’s Study will investigate some of the maternal conditions thought to enhance cardiovascular risk in offspring, in particular maternal diabetic conditions, oxidative stress, and inflammation, but it will focus on outcomes that are most prevalent in childhood such as diabetes mellitus, not on cardiovascular risk, which can only be extrapolated from the early consequences of developmental programming (the Figure). Even under the most optimistic conditions, it will not be feasible to carry out large-scale clinical trials for each putative maternal risk factor and to extend them to the onset of clinical manifestations. The contribution of the Barker hypothesis and the extensive epidemiological work validating it has been to prove, in principle, that developmental programming matters for cardiovascular disease. It is now time to complement human epidemiology by studies focusing on intervention and mechanistic studies in experimental models. This should enable us not only to elucidate the in utero programming mechanisms but also to identify potential new targets for prevention that go beyond the standard advice to treat preexisting maternal conditions. After all, interventions targeting developmental programming are most appealing because they may yield lifelong benefits yet involve very little risk for the fetus when effected before pregnancy.

Sources of Funding
We thank the National Institutes of Health for grant HL-067792 (Fetal Determinants of Atherosclerosis), the Ellison Medical Foundation for a Senior Investigator award (Dr Palinski), and the Fondation for a Senior Investigator award (Dr Palinski), and the Ellison Medical Foundation (Fetal Determinants of Atherosclerosis), the Ellison Medical Foundation for a Senior Investigator award (Dr Palinski), and the Fondation Jerome Lejeune (Dr Napoli). We thank the National Institutes of Health for grant HL-067792 (Fetal Determinants of Atherosclerosis), the Ellison Medical Foundation for a Senior Investigator award (Dr Palinski), and the Fondation Jerome Lejeune (Dr Napoli).

Disclosures
None.

References

Key Words: Editorials ■ cardiovascular diseases ■ pregnancy ■ prevention ■ risk factors

Downloaded from http://circ.ahajournals.org/ by guest on January 13, 2018
Impaired Fetal Growth, Cardiovascular Disease, and the Need to Move on
Wulf Palinski and Claudio Napoli

Circulation. 2008;117:341-343
doi: 10.1161/CIRCULATIONAHA.107.750133
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/117/3/341

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/